By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia has filed for an initial public offering to sell shares on the NYSE Euronext in Amsterdam.

The Dutch molecular diagnostics firm plans to sell up to 4,587,156 newly issued ordinary shares at a price of between €16.35 to €19.15 per share. At the mid-point of that range, it would raise around €81.4 million ($119 million), before an over-allotment option of up to 688,073 newly issued ordinary shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.